Fate Therapeutics (NASDAQ:FATE) Stock Rating Reaffirmed by Needham & Company LLC

Needham & Company LLC restated their hold rating on shares of Fate Therapeutics (NASDAQ:FATE – Free Report) in a research report released on Thursday, Benzinga reports. A number of other equities analysts also recently issued reports on FATE. Oppenheimer reissued a market perform rating on shares of Fate Therapeutics in a report on Tuesday, February […]

Related Keywords

,Financial Services Group Inc ,Advisor Group ,Envestnet Asset Management Inc ,Fate Therapeutics Inc ,Raymond James Associates ,Needham Company ,Hightower Advisors ,Barclays ,Morgan Stanley ,Fate Therapeutics ,Free Report ,Get Free Report ,Asset Management ,Tower Advisors ,Services Group ,Fate Therapeutics Daily ,Nasdaq Fate ,Fate ,Medical ,Reiterated Rating ,Needham Company Llc ,